WES of human NSCLC cell lines that have acquired resistant to KRAS G12C inhibitors

Public description: Human NSCLC cell lines were chronically treated with sotorasib, RMC-4998, or a combination of sotorasib and RMC-4550 to generate resistant models. The cells were then subjected to whole-exome sequencing (WES) to identify acquired genomic alterations. Additionally, resistant cell lines were derived from sotorasib-treated, relapsed H358 mouse xenograft tumors, and WES was performed on these as well to investigate the associated genomic changes.